Lee Financial Co Sells 30 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Lee Financial Co lowered its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 7.0% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 397 shares of the medical research company’s stock after selling 30 shares during the quarter. Lee Financial Co’s holdings in Thermo Fisher Scientific were worth $207,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in TMO. MN Wealth Advisors LLC boosted its holdings in shares of Thermo Fisher Scientific by 6.3% in the 4th quarter. MN Wealth Advisors LLC now owns 440 shares of the medical research company’s stock worth $229,000 after acquiring an additional 26 shares in the last quarter. Secured Retirement Advisors LLC raised its position in Thermo Fisher Scientific by 19.4% in the 4th quarter. Secured Retirement Advisors LLC now owns 3,779 shares of the medical research company’s stock valued at $1,966,000 after purchasing an additional 613 shares during the last quarter. Strategic Financial Concepts LLC bought a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth $246,000. Allworth Financial LP increased its stake in shares of Thermo Fisher Scientific by 183.6% in the fourth quarter. Allworth Financial LP now owns 18,783 shares of the medical research company’s stock valued at $10,792,000 after buying an additional 12,160 shares in the last quarter. Finally, Principal Securities Inc. lifted its position in Thermo Fisher Scientific by 9.2% during the 4th quarter. Principal Securities Inc. now owns 9,058 shares of the medical research company’s stock worth $4,712,000 after buying an additional 766 shares in the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CFO Stephen Williamson sold 9,825 shares of the business’s stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total transaction of $5,753,421.75. Following the sale, the chief financial officer now directly owns 27,296 shares of the company’s stock, valued at $15,984,264.64. The trade was a 26.47 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $530.26, for a total value of $5,302,600.00. Following the completion of the transaction, the chief executive officer now owns 111,192 shares of the company’s stock, valued at $58,960,669.92. The trade was a 8.25 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 20,125 shares of company stock valued at $11,231,699. 0.34% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on TMO. Raymond James reaffirmed an “outperform” rating and issued a $667.00 target price (up from $650.00) on shares of Thermo Fisher Scientific in a research note on Monday, February 3rd. Citigroup boosted their price objective on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock a “neutral” rating in a research report on Friday, January 31st. Sanford C. Bernstein upgraded Thermo Fisher Scientific from a “market perform” rating to an “outperform” rating and set a $630.00 price objective on the stock in a research report on Friday, January 10th. Bernstein Bank upped their price target on Thermo Fisher Scientific from $565.00 to $625.00 and gave the company a “market perform” rating in a research note on Tuesday, October 22nd. Finally, StockNews.com upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Tuesday, January 14th. Four equities research analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and a consensus target price of $658.00.

Thermo Fisher Scientific Stock Performance

Shares of TMO stock opened at $532.58 on Friday. The company has a market capitalization of $203.71 billion, a P/E ratio of 32.22, a price-to-earnings-growth ratio of 3.18 and a beta of 0.77. Thermo Fisher Scientific Inc. has a 52 week low of $493.30 and a 52 week high of $627.88. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66. The company’s 50 day moving average price is $548.51 and its two-hundred day moving average price is $570.52.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share for the quarter, topping analysts’ consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. On average, analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific declared that its board has authorized a stock buyback program on Friday, November 15th that authorizes the company to buyback $4.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to reacquire up to 2% of its shares through open market purchases. Shares buyback programs are generally a sign that the company’s leadership believes its shares are undervalued.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.